menu
    • menu
    [{"orgOrder":0,"company":"Servier Canada","sponsor":"Cellectis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"UCART19","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Servier Canada","amount2":0.40999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Servier Canada \/ Servier ","highestDevelopmentStatusID":"6","companyTruncated":"Servier Canada \/ Servier "},{"orgOrder":0,"company":"Servier Canada","sponsor":"Symphogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Sym021","moa":"PD1","graph1":"Oncology","graph2":"Phase I","graph3":"Servier Canada","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Servier Canada \/ Servier ","highestDevelopmentStatusID":"6","companyTruncated":"Servier Canada \/ Servier "}]

    Find Clinical Drug Pipeline Developments & Deals by Servier Canada

    Menu

    Servier Canada

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Servier Canada

                            Canada arrow
                            BMWS24
                            Not Confirmed

                            Servier Canada

                            Canada arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sym021

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Symphogen

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Servier Agrees to Buy Symphogen to Swell its Cancer Pipeline

                            Details : Servier will gain full ownership of Symphogen’s proprietary pipeline of oncology and immuno-oncology programs and Symphogen’s antibody discovery and development platform.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 03, 2020

                            Lead Product(s) : Sym021

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Symphogen

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Servier Canada

                            Canada arrow
                            BMWS24
                            Not Confirmed

                            Servier Canada

                            Canada arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UCART19

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Cellectis

                            Deal Size : $410.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Product...

                            Details : Cellectis grants to Servier an expanded exclusive worldwide license to develop and commercialize all next generation gene-edited allogeneic CAR T-cell products targeting CD19.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $27.6 million

                            March 04, 2020

                            Lead Product(s) : UCART19

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Cellectis

                            Deal Size : $410.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth